Literature DB >> 22000822

Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.

Marta Perek-Polnik1, Sergiusz Jóźwiak, Elżbieta Jurkiewicz, Danuta Perek, Katarzyna Kotulska.   

Abstract

We present successful everolimus treatment of a huge subependymal giant cell astrocytoma in a 10-year old boy with tuberous sclerosis complex. The patient underwent several partial tumor resections complicated by intraoperative cardiac arrest. The tumor has been regrowing and produced severe clinical symptoms. Everolimus treatment resulted in marked tumor regression, significant improvement in patient's ambulation and cessation of seizures. Moreover, the therapy was well tolerated. These findings indicate that everolimus treatment should be considered as a therapeutic option alternative to surgery in patients with tuberous sclerosis complex.
Copyright © 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22000822     DOI: 10.1016/j.ejpn.2011.09.006

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  20 in total

Review 1.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein levels, CSF clotting, and communicating hydrocephalus: a comprehensive review.

Authors:  Yosef Laviv; Burkhard S Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-07       Impact factor: 3.042

Review 2.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 3.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Authors:  Paolo Curatolo; Marit Bjørnvold; Patricia E Dill; José Carlos Ferreira; Martha Feucht; Christoph Hertzberg; Anna Jansen; Sergiusz Jóźwiak; J Christopher Kingswood; Katarzyna Kotulska; Alfons Macaya; Romina Moavero; Rima Nabbout; Bernard A Zonnenberg
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 4.  Medical treatment of tuberous sclerosis-related epilepsy.

Authors:  Shimrit Uliel-Sibony; Veronika Chernuha; Hadas Meirson; Aviva Fattal-Valevski
Journal:  Childs Nerv Syst       Date:  2020-08-22       Impact factor: 1.475

5.  mTOR as a potential treatment target for epilepsy.

Authors:  Michael Wong
Journal:  Future Neurol       Date:  2012-09-01

Review 6.  Tuberous sclerosis complex: the past and the future.

Authors:  Liesbeth De Waele; Lieven Lagae; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2014-12-23       Impact factor: 3.714

Review 7.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

Review 8.  Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang; Kenneth Maiese
Journal:  Prog Neurobiol       Date:  2012-08-15       Impact factor: 11.685

Review 9.  A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.

Authors:  Michael Wong
Journal:  Expert Rev Neurother       Date:  2013-06       Impact factor: 4.618

Review 10.  Advances in the management of subependymal giant cell astrocytoma.

Authors:  Thomas L Beaumont; David D Limbrick; Matthew D Smyth
Journal:  Childs Nerv Syst       Date:  2012-05-05       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.